KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Short-term Investments: 2009-2024

Historic Short-term Investments for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $6.5 billion.

  • Regeneron Pharmaceuticals' Short-term Investments fell 23.73% to $5.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 billion, marking a year-over-year decrease of 23.73%. This contributed to the annual value of $6.5 billion for FY2024, which is 19.60% down from last year.
  • Regeneron Pharmaceuticals' Short-term Investments amounted to $6.5 billion in FY2024, which was down 19.60% from $8.1 billion recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' Short-term Investments registered a high of $8.1 billion during FY2023, and its lowest value of $1.4 billion during FY2020.
  • Moreover, its 3-year median value for Short-term Investments was $6.5 billion (2024), whereas its average is $6.4 billion.
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Short-term Investments spiked by 101.61% in 2021 and then fell by 19.60% in 2024.
  • Regeneron Pharmaceuticals' Short-term Investments (Yearly) stood at $1.4 billion in 2020, then surged by 101.61% to $2.8 billion in 2021, then surged by 65.05% to $4.6 billion in 2022, then skyrocketed by 75.02% to $8.1 billion in 2023, then dropped by 19.60% to $6.5 billion in 2024.